VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial

by NASDAQ Market News April 15, 2020

NASDAQ Market News
Click here to email author

Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon™ hGH as Treatment for Growth Hormone Deficiency in the United States

The Global Nephrology Devices Market is expected to grow from USD 11,952.37 Million in 2019 to USD 17,226.74 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.28%

Ads